This is a StreetInsider.com Premium Only Page

Alexion Pharma (ALXN) – Business Wire

Jul 15, 2021 04:05 PM Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

Jun 11, 2021 03:01 AM Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

Jun 7, 2021 01:55 PM  Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

May 12, 2021 04:14 PM Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

May 12, 2021 04:01 PM Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress

May 11, 2021 09:28 AM Alexion Shareholders Approve Acquisition by AstraZeneca

Apr 30, 2021 08:00 AM Alexion Reports First Quarter 2021 Results

Apr 28, 2021 05:00 PM UPDATED Alexion to Report First Quarter 2021 Results on Friday, April 30, 2021

Apr 20, 2021 08:00 AM Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021

Mar 4, 2021 04:56 PM Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology

Feb 17, 2021 06:50 AM ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth

Feb 4, 2021 08:00 AM Alexion Reports Fourth Quarter and Full Year 2020 Results

Jan 25, 2021 04:05 PM Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021

Jan 13, 2021 04:20 PM Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19

Jan 12, 2021 07:00 AM  Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference

Jan 5, 2021 04:30 PM Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference

Dec 12, 2020 07:48 AM AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development

Nov 20, 2020 02:00 AM Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time

Nov 10, 2020 07:00 AM Alexion to Present at Upcoming Virtual Investor Conferences

Nov 4, 2020 11:55 AM Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

Nov 4, 2020 11:50 AM Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

Oct 29, 2020 06:30 AM Alexion Reports Third Quarter 2020 Results

Oct 20, 2020 04:30 PM Alexion to Report Third Quarter 2020 Results on Thursday, October 29, 2020

Oct 12, 2020 08:30 AM Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time

Oct 9, 2020 02:00 PM Alexion Announces Upcoming Data Presentations at the American Society of Nephrology’s Virtual Kidney Week 2020

Oct 6, 2020 06:30 AM Alexion Highlights Promising Pipeline & Distinguished Rare Disease Capabilities at Virtual Investor Day

Sep 25, 2020 08:30 AM ULTOMIRIS® (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children

Sep 21, 2020 02:00 AM Alexion Receives CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time

Sep 14, 2020 08:00 AM Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

Sep 14, 2020 07:00 AM Alexion to Discuss Key Pipeline Programs at Virtual Investor Day

Sep 9, 2020 08:30 AM  Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting

Sep 3, 2020 06:30 AM Alexion to Present at Upcoming Virtual Investor Conferences

Aug 6, 2020 08:00 AM Alexion Announces Appointment of First Chief Diversity Officer

Jul 30, 2020 06:30 AM Alexion Reports Second Quarter 2020 Results

Jul 16, 2020 06:30 AM Alexion to Report Second Quarter 2020 Results on Thursday, July 30, 2020

Jul 2, 2020 08:45 AM Alexion Completes Acquisition of Portola

Jun 29, 2020 02:00 AM ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS)

Jun 24, 2020 09:12 AM Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint

Jun 17, 2020 08:30 AM Alexion Charitable Foundation Announces First Rare Belonging® Grants

Jun 17, 2020 06:30 AM Alexion to Present at the 2020 Bank of America Virtual Napa Biotech Conference

Jun 4, 2020 06:30 AM Alexion to Present at the 41st Annual Global Goldman Sachs Healthcare Conference

May 14, 2020 09:31 AM Alexion Announces Upcoming Data Presentations at the Virtual 25th Congress of the European Hematology Association

May 6, 2020 06:30 AM Alexion Reports First Quarter 2020 Results

May 5, 2020 04:30 PM Alexion to Present at the Virtual Bank of America Securities 2020 Healthcare Conference

May 5, 2020 07:00 AM Alexion to Acquire Portola

May 1, 2020 08:30 AM Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)

Apr 20, 2020 08:30 AM Alexion Announces Plans to Initiate Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19

Apr 9, 2020 05:25 PM Alexion to Report First Quarter Results and Provide Update on COVID-19 on Wednesday, May 6th, 2020

Mar 5, 2020 06:25 PM  Alexion Announces Upcoming Data Presentations at 72nd Annual Meeting of the American Academy of Neurology

Feb 27, 2020 08:30 AM Alexion Announces Launch of Alexion Charitable Foundation and Calls for Grantees